Lexaria gets AUD$3.7M Australian R&D tax credit
Rhea-AI Filing Summary
Lexaria Bioscience Corp. (LEXX) disclosed that its wholly owned Australian subsidiary, Lexaria (AU) Pty Ltd, received an Australian R & D Tax Incentive Credit of AUD$3,666,611.98 on August 28, 2026. The credit relates to research and development costs for its Australian clinical study GLP-1-H24-4.
The funds have been deposited into the subsidiary’s Australian bank account and are intended to be used to pursue additional research and development opportunities in Australia. Lexaria (AU) holds the exclusive rights to use DehydraTECH technology with pharmaceutical GLP-1/GIP and CBD drug products in Australia.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Australian R & D Tax Incentive Credit: AUD$3,666,611.98
Date of receipt of tax credit: August 28, 2026
Par value of Common Stock: $0.001 per share
+1 more
4 metrics
Australian R & D Tax Incentive Credit
AUD$3,666,611.98
Amount received by Lexaria (AU) Pty Ltd related to clinical study GLP-1-H24-4
Date of receipt of tax credit
August 28, 2026
Date Lexaria (AU) Pty Ltd received the Australian R & D Tax Incentive Credit
Par value of Common Stock
$0.001 per share
Par value of Lexaria Bioscience Corp. common stock listed on The Nasdaq Capital Market
Registrant telephone number
(250) 765-6424
Telephone number for Lexaria Bioscience Corp.’s principal executive offices
Key Terms
Australian R & D Tax Incentive Credit, DehydraTECH technology, GLP-1/GIP, GLP-1-H24-4
4 terms
Australian R & D Tax Incentive Credit financial
"received a tax credit in the amount of AUD$3,666,611.98 from the Australian Tax Office"
DehydraTECH technology technical
"holds the exclusive rights to use DehydraTECH technology with pharmaceutical GLP-1/GIP"
GLP-1/GIP medical
"use DehydraTECH technology with pharmaceutical GLP-1/GIP and CBD drug products"
GLP-1-H24-4 medical
"research and development costs associated with its Australian clinical study GLP-1-H24-4"
FAQ
What tax credit did Lexaria Bioscience Corp. (LEXX) receive in Australia?
Lexaria’s Australian subsidiary received an Australian R & D Tax Incentive Credit of AUD$3,666,611.98 related to research and development costs for its clinical study GLP-1-H24-4.
When did LEXX receive the Australian R & D Tax Incentive Credit?
Lexaria (AU) Pty Ltd received the Australian R & D Tax Incentive Credit on August 28, 2026, from the Australian Tax Office in connection with research and development costs for study GLP-1-H24-4.
How much was the Australian R & D Tax Incentive Credit received by LEXX?
Lexaria’s Australian subsidiary received a tax credit of AUD$3,666,611.98 under the Australian R & D Tax Incentive program, tied to R&D expenses for its clinical study GLP-1-H24-4.
How will Lexaria Bioscience Corp. (LEXX) use the Australian tax credit funds?
The AUD$3,666,611.98 tax credit has been deposited into Lexaria (AU) Pty Ltd’s Australian bank account and is intended for pursuing additional research and development opportunities in Australia.
What exclusive rights does Lexaria (AU) Pty Ltd hold for LEXX in Australia?
Lexaria (AU) Pty Ltd holds the exclusive rights to use DehydraTECH technology with pharmaceutical GLP-1/GIP and CBD drug products in the territory of Australia.
Which Lexaria study is linked to the Australian R & D Tax Incentive Credit for LEXX?
The credit is linked to research and development costs associated with Lexaria’s Australian clinical study GLP-1-H24-4, for which Lexaria (AU) Pty Ltd received the R & D Tax Incentive Credit.
AI-generated analysis. How Rhea-AI works. Not financial advice.
